News Quantified

PULM – pulmatrix, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Pulmatrix Announces Year-End and Fourth Quarter 2024 Financial Results and Divestment Plan for Assets

PULM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Pulmatrix, Inc. Is Fair to Shareholders

Cullgen Begins Phase 1 Dosing of its Potential First-in-Class, Oral Pan-TRK Protein Degrader for Acute and Chronic Pain

Pulmatrix, Inc. (NASDAQ: PULM) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.

Form 10-K Pulmatrix, Inc. For: Dec 31

Form 8-K Pulmatrix, Inc. For: Mar 21

Form S-4 Pulmatrix, Inc.

Form 8-K Pulmatrix, Inc. For: Feb 11

Form 425 Pulmatrix, Inc. Filed by: Pulmatrix, Inc.

Top News Gainers

1/2 Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson 86.2%

4/1 Pulmatrix Inc (NASDAQ: PULM) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 24.3%

4/15 Form 8-K Pulmatrix, Inc. For: Apr 09 9.9%

8/22 Form 8-K Pulmatrix, Inc. For: Aug 22 8.1%

4/24 Form D Pulmatrix, Inc. 8.0%

1/6 Pulmatrix Announces Research Collaboration with Nocion Therapeutics to Explore Inhaled Drug Delivery Technologies 7.4%

11/19 Form 8-K Pulmatrix, Inc. For: Nov 19 7.3%

4/29 Form DEF 14A Pulmatrix, Inc. For: Jun 17 6.6%

10/30 Form 8-K Pulmatrix, Inc. For: Oct 25 5.5%

11/18 Form 8-K Pulmatrix, Inc. For: Nov 13 4.9%

Top News Decliners

4/16 Pulmatrix Announces $8.0 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules -28.6%

3/26 Form 10-K Pulmatrix, Inc. For: Dec 31 -15.7%

1/30 Pulmatrix Receives Fast Track Designation for Pulmazole for the Treatment of Asthma-ABPA -12.9%

4/16 Pulmatrix and Sensory Cloud Announce Partnership to Develop and Commercialize a Potential Nasal Prophylactic and Anticontagion Product for COVID-19 -10.2%

4/24 Form SC 13G Pulmatrix, Inc. Filed by: ARMISTICE CAPITAL, LLC -7.7%

8/19 Pulmatrix Receives US Patent Covering iSPERSE™ Formulations for Pulmazole Program -6.7%

3/9 Pulmatrix Inc (NASDAQ: PULM) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -6.5%

11/1 Q3/2019 9/30/2019 EPS -0.180 ZacksConsensus N/A ActVsEst N/A - N/A -6.5%

2/11 Form SC 13G/A Pulmatrix, Inc. Filed by: INTRACOASTAL CAPITAL, LLC -6.0%

11/14 Pulmatrix Inc (NASDAQ: PULM) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.00 price target on the stock. -5.6%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day